key: cord-1020856-0c1itmq7 authors: Chiao, Cassandra; Faust, Hilary; Singh, Tripti title: Regional citrate and systemic heparin are adequate to maintain filter half‐life for COVID‐19 patients on continuous renal replacement therapy date: 2022-02-09 journal: Semin Dial DOI: 10.1111/sdi.13061 sha: 934eb24e18f002fddbc06d201d8f10c86c5201fd doc_id: 1020856 cord_uid: 0c1itmq7 INTRODUCTION: The aim of our study is to compare clotting of CRRT filters in patients with COVID‐19‐associated AKI versus septic shock‐associated AKI. METHODS: Retrospective study of adult ICU patients with COVID‐19 compared to those with septic shock admitted to a tertiary hospital April–October 2020. Independent t test and chi‐square test used to determine statistical significance of CRRT filter clotting between the two groups. Time‐to‐event data analyzed with Kaplan–Meier curves. Analyses performed on Microsoft Excel and MedCalc. RESULTS: Twenty‐seven ICU patients with AKI requiring CRRT were included, 13 with COVID‐19 and 14 non‐COVID‐19 patients with septic shock. The mean half‐life of CRRT hemofilter was similar in COVID‐19 patients compared to non‐COVID‐19 patients (27.4 vs. 27.5 h, p = 0.79). The number of CRRT hemofilter changes per day was similar in both groups (0.6 filter changes per day, p = 0.84). However, significantly more patients with COVID‐19 were on systemic heparin (69% vs. 13%, p = 0.02). CONCLUSION: We found that COVID‐19 patients with AKI requiring CRRT had similar CRRT hemofilter half‐life compared with sepsis‐associated AKI patients with use of regional citrate and systemic heparin. Further studies are needed to find which methods of anticoagulation are optimal in patients with COVID‐19 infection with AKI requiring CRRT. Coronavirus-19 disease (COVID-19), caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), results in a range of presentations varying from asymptomatic to severe critical illness characterized by cytokine storm, acute respiratory distress syndrome, respiratory failure, septic shock, and acute kidney injury (AKI). [1] [2] [3] Coagulopathy manifested as pulmonary embolism, cerebral infarct, disseminated intravascular coagulopathy (DIC), or pulmonary microvascular thrombosis and hemorrhage is a major complication of severe disease in COVID-19 infection. [4] [5] [6] Patients with COVID-19 disease, multiorgan dysfunction, and severe AKI commonly require continuous renal replacement therapy (CRRT). 1 Anecdotal reports suggest that clotting of CRRT hemofilter resulting in decreased hemofilter half-life is more in COVID-19 patients compared to other critically ill patients with AKI requiring CRRT. Increased clotting of CRRT hemofilter leads to reduced time on CRRT and blood loss, worsening the anemia of critical illness and increasing need for blood transfusion. 7 The study population included all patients with AKI requiring CRRT and confirmed COVID-19 infection or with septic shock using the Sepsis 3 guidelines with laboratory-confirmed negative COVID-19 admitted to the medical intensive care unit between April 2020 and October 2020 at our institution. COVID-19 infection was defined by a positive reverse transcription-polymerase chain reaction (RT-PCR) assay of a specimen collected on a nasopharyngeal swab or a tracheal aspirate. The University of Wisconsin-Madison Institutional Review Board and the Human Subjects Committee exempted the study. Demographic data, laboratory data, CRRT administration data, and medications administered during ICU admission were obtained from the institution's electronic medical record. Nx Stage 505 filter was used with CRRT. All laboratory tests, CRRT administration, and medication use were at the discretion of the treating physician. Use of regional citrate for anticoagulation with CRRT is the standard of practice at our institution. However, initial start of A total of 27 patients with AKI requiring CRRT were included in the study, 13 with COVID-19 infection and 14 with septic shock. The mean age in the COVID-19 patients was 55.1 years, 10 (77%) were male, mean BMI was 40.7, two (15%) had CKD, four (31%) had diabetes mellitus, five (39%) had hypertension, two (15%) had cardiovascular disease (CVD), and three (23%) were immunocompromised (from kidney transplant, asplenia, or use of biologic therapy). The mean age of non-COVID-19 patients was 59.6 years, nine (60%) were male, mean BMI was 35.1, five (33%) had CKD, three (20%) had diabetes mellitus, seven (47%) had hypertension, one (7%) had CVD, four (27%) had cirrhosis, and two (13%) were immunocompromised (both solid organ transplant patients on immunosuppressants). There were no significant differences between LDH and D-dimer between the two groups, both at admission and just prior to the start of CRRT (shown in Table 1 ). The COVID-19 patients required CRRT at 5.9 days after admission compared to 6.1 days for non-COVID-19 patients (p = 0.94). Mean SOFA scores were similar between the two groups (12. We found that mean half-life of CRRT hemofilter in COVID-19 patients was similar to non-COVID-19 patients with septic shock and AKI requiring CRRT. The use of regional citrate with CRRT as an anti- In summary, COVID-19 patients with AKI requiring CRRT had similar CRRT hemofilter half-life compared with sepsis-associated AKI patients with use of regional citrate anticoagulation and systemic heparin use. Further studies are need to find which methods of anticoagulation are optimal in patients with COVID-19 infection with AKI requiring CRRT. No funding sources reported by any of the authors. No conflicts of interest reported by any of the authors. The University of Wisconsin-Madison Institutional Review Board and the Human Subjects Committee exempted the study. Cassandra Chiao https://orcid.org/0000-0003-4186-0667 Acute kidney injury in patients hospitalized with COVID-19 Covid-19 and acute kidney injury in hospital: summary of NICE guidelines Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia Solute clearance in CRRT: prescribed dose versus actual delivered dose Effluent volume in continuous renal replacement therapy overestimates the delivered dose of dialysis Renal involvement and early prognosis in patients with COVID-19 pneumonia Therapeutic anticoagulation in critically Ill patients with Covid-19-preliminary report Regional citrate and systemic heparin are adequate to maintain filter half-life for COVID-19 patients on continuous renal replacement therapy